153 related articles for article (PubMed ID: 29693274)
21. MicroRNA-17 inhibition overcomes chemoresistance and suppresses epithelial-mesenchymal transition through a DEDD-dependent mechanism in gastric cancer.
Wu DM; Hong XW; Wang LL; Cui XF; Lu J; Chen GQ; Zheng YL
Int J Biochem Cell Biol; 2018 Sep; 102():59-70. PubMed ID: 29953965
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-182 is a potential biomarker for prognosis of gastric cancer: A protocol for meta-analysis and bioinformatics analysis.
Xiao D; Xie J; Wu S
Medicine (Baltimore); 2021 Jun; 100(22):e25830. PubMed ID: 34087825
[TBL] [Abstract][Full Text] [Related]
23. Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN.
Jin YY; Chen QJ; Xu K; Ren HT; Bao X; Ma YN; Wei Y; Ma HB
Mol Cell Biochem; 2016 Nov; 422(1-2):161-170. PubMed ID: 27644195
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9.
Wang J; Xue X; Hong H; Qin M; Zhou J; Sun Q; Liang H; Gao L
Oncotarget; 2017 Jan; 8(1):574-582. PubMed ID: 27880941
[TBL] [Abstract][Full Text] [Related]
25. MiR-375: A prospective regulator in medullary thyroid cancer based on microarray data and bioinformatics analyses.
Shi L; Zhao SM; Luo Y; Zhang AW; Wei LH; Xie ZY; Li YY; Ma W
Pathol Res Pract; 2017 Nov; 213(11):1344-1354. PubMed ID: 29033189
[TBL] [Abstract][Full Text] [Related]
26. Identification of a nine-miRNA signature for the prognosis of Uveal Melanoma.
Xin X; Zhang Y; Ling F; Wang L; Sheng X; Qin L; Zhao X
Exp Eye Res; 2019 Mar; 180():242-249. PubMed ID: 30615885
[TBL] [Abstract][Full Text] [Related]
27. MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1.
Zhang Y; Xu W; Ni P; Li A; Zhou J; Xu S
Int J Biol Sci; 2016; 12(12):1437-1447. PubMed ID: 27994509
[TBL] [Abstract][Full Text] [Related]
28. MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2.
Wen L; Cheng F; Zhou Y; Yin C
Saudi J Gastroenterol; 2015; 21(5):313-9. PubMed ID: 26458859
[TBL] [Abstract][Full Text] [Related]
29. Identification and Analysis of Key Genes Driving Gastric Cancer Through Bioinformatics.
Liu Z; Liu S; Guo J; Sun L; Wang S; Wang Y; Qiu W; Lv J
Genet Test Mol Biomarkers; 2021 Jan; 25(1):1-11. PubMed ID: 33470887
[No Abstract] [Full Text] [Related]
30. The clinical significance of miR-335, miR-124, miR-218 and miR-484 downregulation in gastric cancer.
Zare A; Ahadi A; Larki P; Omrani MD; Zali MR; Alamdari NM; Ghaedi H
Mol Biol Rep; 2018 Dec; 45(6):1587-1595. PubMed ID: 30171475
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells.
Yang X; Cai H; Liang Y; Chen L; Wang X; Si R; Qu K; Jiang Z; Ma B; Miao C; Li J; Wang B; Gao P
Oncol Rep; 2015 Apr; 33(4):1723-30. PubMed ID: 25633261
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA network analysis identifies key microRNAs and genes associated with precancerous lesions of gastric cancer.
Wang XW; Wu Y; Wang D; Qin ZF
Genet Mol Res; 2014 Oct; 13(4):8695-703. PubMed ID: 25366760
[TBL] [Abstract][Full Text] [Related]
33. Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data.
Wang YW; Zhang W; Ma R
Oncol Rep; 2018 Mar; 39(3):1003-1010. PubMed ID: 29328395
[TBL] [Abstract][Full Text] [Related]
34. TRANSCRIPTOME ANALYSIS REVEALED THE MOLECULAR SIGNATURES OF CISPLATIN-FLUOROURACIL COMBINED CHEMOTHERAPY RESISTANCE IN GASTRIC CANCER.
Luo Y; Chen X; Hu E; Wang L; Yang Y; Jiang X; Zheng K; Wang L; Li J; Xu Y; Wang Y; Xie Y
Georgian Med News; 2023 Dec; (345):6-18. PubMed ID: 38325291
[TBL] [Abstract][Full Text] [Related]
35. Identifying
Liu XT; Liu TT; Wu MY; Chen QX; Zhuang JX; Wang Q
Genet Test Mol Biomarkers; 2021 Jan; 25(1):68-78. PubMed ID: 33470885
[No Abstract] [Full Text] [Related]
36. Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer.
Yu C; Xue P; Zhang L; Pan R; Cai Z; He Z; Sun J; Zheng M
World J Surg Oncol; 2018 Aug; 16(1):174. PubMed ID: 30134903
[TBL] [Abstract][Full Text] [Related]
37. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells.
Zheng P; Chen L; Yuan X; Luo Q; Liu Y; Xie G; Ma Y; Shen L
J Exp Clin Cancer Res; 2017 Apr; 36(1):53. PubMed ID: 28407783
[TBL] [Abstract][Full Text] [Related]
38. Integrated MicroRNA-mRNA Analysis Reveals miR-204 Inhibits Cell Proliferation in Gastric Cancer by Targeting CKS1B, CXCL1 and GPRC5A.
Shrestha S; Yang CD; Hong HC; Chou CH; Tai CS; Chiew MY; Chen WL; Weng SL; Chen CC; Chang YA; Lee ML; Huang WY; Hsu SD; Chen YC; Huang HD
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29283424
[TBL] [Abstract][Full Text] [Related]
39. The expression of miR-375 in prostate cancer: A study based on GEO, TCGA data and bioinformatics analysis.
He S; Shi J; Mao J; Luo X; Liu W; Liu R; Yang F
Pathol Res Pract; 2019 Jun; 215(6):152375. PubMed ID: 30879885
[TBL] [Abstract][Full Text] [Related]
40. Genomic instability-related twelve-microRNA signatures for predicting the prognosis of gastric cancer.
Xu J; Song J; Chen X; Huang Y; You T; Zhu C; Shen X; Zhao Y
Comput Biol Med; 2023 Mar; 155():106598. PubMed ID: 36764156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
